Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Chan Whiting, Kim Fischer, Bryan Laffitte, Lisa Rahbaek, Nick Stock, Davorka Messmer, Austin Chen, Traci Olafson, Natalie Nguyen, et al. | ||||||||||||
Title | Dual antagonism of prostaglandin receptors EP2 and EP4 by TPST-1495 suppresses tumor growth and stimulates anti-tumor immunity | ||||||||||||
|
|||||||||||||
URL | https://jitc.bmj.com/content/7/Suppl_1/282 | ||||||||||||
Abstract Text | Journal for ImmunoTherapy of Cancer 2019;7:282, Abs nr: P311 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TPST-1495 | TPST1495|TPST 1495 | TPST-1495 is a dual antagonist that selectively inhibits EP2 and EP4, and reverses Prostaglandin E2 mediated immune suppression, potentially resulting in enhanced antitumor immune response and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2019;7:282, Abs nr: P311). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|